ALKEM.NS Profit & Loss
Alkem Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹11,599.26 Cr. | ₹12,667.58 Cr. | ₹12,964.52 Cr. | ₹14,712.27 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹216.08 Cr. | ₹310.84 Cr. | ₹493.74 Cr. | ₹583.35 Cr. | OtherIncome |
| Total Income | ₹11,815.34 Cr. | ₹12,978.42 Cr. | ₹13,458.26 Cr. | ₹15,295.62 Cr. | Income |
| Cost of Materials Consumed | ₹3,056.92 Cr. | ₹3,294.59 Cr. | ₹3,440.37 Cr. | ₹3,565.39 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹1,387.55 Cr. | ₹1,628.87 Cr. | ₹1,514.02 Cr. | ₹1,694.50 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹462.37 Cr. | ₹14.12 Cr. | ₹-190.13 Cr. | ₹-167.12 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹2,131.35 Cr. | ₹2,201.01 Cr. | ₹2,453.92 Cr. | ₹2,837.11 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹107.36 Cr. | ₹112.41 Cr. | ₹121.70 Cr. | ₹160.78 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹310.42 Cr. | ₹299.30 Cr. | ₹357.16 Cr. | ₹382.06 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹2,951.62 Cr. | ₹3,283.50 Cr. | ₹3,234.19 Cr. | ₹3,777.18 Cr. | OtherExpenses |
| Total Expenses | ₹10,407.59 Cr. | ₹10,833.80 Cr. | ₹10,931.23 Cr. | ₹12,249.90 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹1,407.75 Cr. | ₹2,144.62 Cr. | ₹2,527.03 Cr. | ₹3,045.72 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-102.98 Cr. | ₹-121.49 Cr. | ₹0.00 Cr. | ₹-174.83 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹1,304.77 Cr. | ₹2,023.13 Cr. | ₹2,527.03 Cr. | ₹2,870.89 Cr. | ProfitBeforeTax |
| Tax Expense | ₹297.96 Cr. | ₹211.67 Cr. | ₹311.03 Cr. | ₹517.76 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹1,006.81 Cr. | ₹1,811.46 Cr. | ₹2,215.38 Cr. | ₹2,351.16 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹984.17 Cr. | ₹1,795.77 Cr. | ₹2,165.48 Cr. | ₹2,301.80 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹82.31 | ₹150.19 | ₹181.11 | ₹192.51 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹82.31 | ₹150.19 | ₹181.11 | ₹192.51 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from ALKEM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).